Cognition Therapeutics, Inc. (CGTX)
CGTX Stock Price Chart
Explore Cognition Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CGTX price movements and trends.
CGTX Company Profile
Discover essential business fundamentals and corporate details for Cognition Therapeutics, Inc. (CGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2021
Employees
25.00
Website
https://www.cogrx.comCEO
Lisa Ricciardi
Description
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Financial Timeline
Browse a chronological timeline of Cognition Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.06, while revenue estimate is $5.00m.
Earnings released on 7 May 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 26 Mar 2026
EPS came in at -$0.02 surpassing the estimated -$0.06 by +66.67%.
Earnings released on 6 Nov 2025
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 7 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 7 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%.
Earnings released on 20 Mar 2025
EPS came in at -$0.17 falling short of the estimated -$0.16 by -6.25%.
Earnings released on 13 Nov 2024
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 8 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%.
Earnings released on 7 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.23 by -17.39%.
Earnings released on 26 Mar 2024
EPS came in at -$0.27 surpassing the estimated -$0.38 by +28.95%, while revenue for the quarter reached $372.00k .
Earnings released on 2 Nov 2023
EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.03%.
Earnings released on 8 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.25 by +36.00%.
Earnings released on 4 May 2023
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.53%.
Earnings released on 23 Mar 2023
EPS came in at -$0.20 surpassing the estimated -$0.49 by +59.18%.
Earnings released on 14 Nov 2022
EPS came in at -$0.29 surpassing the estimated -$0.55 by +47.27%.
Earnings released on 9 Aug 2022
EPS came in at -$0.25 surpassing the estimated -$0.31 by +19.35%.
Earnings released on 11 May 2022
EPS came in at -$0.17 surpassing the estimated -$0.27 by +37.04%.
Earnings released on 30 Mar 2022
EPS came in at -$11.74 falling short of the estimated -$0.26 by -4.42k%.
Earnings released on 17 Nov 2021
EPS came in at -$8.12 falling short of the estimated -$0.57 by -1.32k%.
Earnings released on 8 Oct 2021
EPS came in at -$0.07 .
CGTX Stock Performance
Access detailed CGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
